聯亞藥業股份有限公司
Climate Impact & Sustainability Data (2021, 2023)
Reporting Period: 2021
Environmental Metrics
Total Carbon Emissions:798 tons/year reduction in CO2
ESG Focus Areas
- 公司治理
- 產品責任
- 員工關懷
- 社會公益
- 永續環境
Environmental Achievements
- 二氧化碳排放降低約 798 噸/年
- 透過減少冷卻水塔之循環水換水頻率，以降低製程用水量
- 廢棄物減量及回收再利用、製程管路保溫及蒸氣冷凝水回收再利用
Social Achievements
- 遵循政府制定之勞基法、勞工安全衛生法等相關規定保障本公司員工法定權利
- 訂定及實施合理員工福利措施，包括薪酬、休假及其他福利等，並將經營績效或成果適當反映於員工薪酬
- 提供員工安全與健康之工作環境，並對員工定期實施安全與健康教育
- 為員工建立有效之職涯能力發展培訓計畫
- 重視多元文化，進用外籍人士、身障人士與原住民族。男女性員工採同工同酬的薪酬制度與平等晉升機制
Governance Achievements
- 107 年 10 月 3 日起設立審計委員會，健全公司治理
- 提升資訊透明度，建立發言人制度
- 完成 2021 年企業社會責任報告書
Climate Goals & Targets
Long-term Goals:
- 自行開發之新創藥品取得藥證、商業量產，特殊學名藥拓展全球市場
- 創新長效生物藥品(Biobetter)產品線上市
Medium-term Goals:
- 自行開發之特殊學名藥、生物相似藥取得藥證、商業量產
- 將本公司蛋白質藥品開發技術平台快速地運用於開發專利即將或已經到期的蛋白質生物相似性藥品開發
Short-term Goals:
- 拓展現有銷售中藥品之國際市場
- 拓展美國特殊針劑藥證(ANDA)申請之委託製造服務業務
- 提供蛋白質藥物的高端製藥開發服務
Environmental Challenges
- 國內藥廠大多以生產學名藥、供應台灣內需市場為主，國產學名藥仍低於 30%
- 台灣在藥品外銷上遇到印度、中國等強勁對手，以低廉的成本和價格為最大優勢
- 近年來台灣製藥產業在國際間受到中國及印度藥品的低價競爭，在國內又受到健保藥價管制，使得藥品利潤受到壓縮
Mitigation Strategies
- 開發具有高門檻技術產品，著重具差異化獨特藥品之研發，區別藥品市場，避免多項競爭者造成之競價循環
- 著重新劑型、新複方藥品研發，跳脫傳統學名藥市場，免於原開發廠之排擠
- 擴大經濟規模，妥善利用高通量之新產線承接大批量產品之生產，以進一步提升毛利率
- 積極推動國際化行銷
- 積極與國內外原、物料上游廠商合作，確保原物料穩定供應及最優價格
- 與通路商及經銷商洽談合作開發，直接開發市場最有潛力產品
Supply Chain Management
Supplier Audits: 100%
Responsible Procurement
- 供應商評估
- 供應商稽核
- 供應商訓練
- 供應商表揚
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: GRI
Certifications: PIC/s GMP
Awards & Recognition
- 第十二屆國家品牌玉山獎及全國首獎
- 第十三屆國家品牌獎最佳產品類全國首獎及玉山獎
- 2016 傑出生技產業獎年度創新獎
- 第 15 屆國家新創獎-產業新創獎
- 台灣金根獎之企業獎
- 2022 年 APAC 十大製藥代工公司之一
Reporting Period: 2023
Environmental Metrics
Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed
ESG Focus Areas
- Not disclosed
Environmental Achievements
- Completed the first greenhouse gas emission inventory report in 2022.
Social Achievements
- Not disclosed
Governance Achievements
- Established a spokesperson system and strengthened information transparency.
Climate Goals & Targets
Long-term Goals:
- Develop difficult generic drugs and new dosage forms.
- Introduce advanced technologies such as gene therapy and cell therapy.
- Strengthen the company's new drug development business and increase international exposure.
Medium-term Goals:
- Obtain US FDA approval for MD27 and MD21.
- Expand CDMO business in the US and other international markets.
- Develop new products with niche markets and obtain US FDA approval.
Short-term Goals:
- Obtain Taiwan BLA for UB-851 erythropoietin and optimize production costs.
- Obtain GMP certification for the second vial production line and start mass production.
- Expand international markets for existing products.
Environmental Challenges
- US distributor transition period impacted 2023 revenue from MD19.
- Second vial production line completed installation and trial production but not yet GMP certified.
- Impact of external competition, regulatory environment, and overall business environment.
Mitigation Strategies
- Completed distributor adjustment at the end of 2023, actively deploying MD19 in the US market.
- Planning to obtain GMP certification for the second vial production line in 2024.
- Actively monitoring domestic and international industry development trends, policies, and regulatory changes.
Supply Chain Management
Supplier Audits: 100% of suppliers in 2023 met requirements
Responsible Procurement
- Supplier Code of Conduct, GMP compliance
Climate-Related Risks & Opportunities
Physical Risks
- Not disclosed
Transition Risks
- Not disclosed
Opportunities
- Not disclosed
Reporting Standards
Frameworks Used: GRI
Certifications: PIC/s GMP
Third-party Assurance: Not disclosed
UN Sustainable Development Goals
- Not disclosed
Not disclosed
Sustainable Products & Innovation
- Not disclosed
Awards & Recognition
- Not disclosed